Tango Therapeutics, Inc.Tango Therapeutics, Inc.Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪829.20 M‬USD
−1.10USD
‪−101.74 M‬USD
‪36.53 M‬USD
‪54.88 M‬
Beta (1Y)
−0.72

About Tango Therapeutics, Inc.

CEO
Barbara L. Weber
Headquarters
Boston
Employees (FY)
140
Founded
2017
FIGI
BBG00WFDDRS0
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TNGX is 7.76 USD — it has decreased by 0.13% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tango Therapeutics, Inc. stocks are traded under the ticker TNGX.
Tango Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
TNGX stock is 4.14% volatile and has beta coefficient of −0.72. Check out the list of the most volatile stocks — is Tango Therapeutics, Inc. there?
TNGX earnings for the last quarter are −0.23 USD per share, whereas the estimation was −0.34 USD resulting in a 31.75% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about Tango Therapeutics, Inc. earnings.
Tango Therapeutics, Inc. revenue for the last quarter amounts to ‪10.73 M‬ USD despite the estimated figure of ‪7.59 M‬ USD. In the next quarter revenue is expected to reach ‪8.24 M‬ USD.
Yes, you can track Tango Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TNGX stock has risen by 4.86% compared to the previous week, the month change is a 0.91% rise, over the last year Tango Therapeutics, Inc. has showed a 122.35% increase.
TNGX net income for the last quarter is ‪−30.76 M‬ USD, while the quarter before that showed ‪−22.26 M‬ USD of net income which accounts for −38.18% change. Track more Tango Therapeutics, Inc. financial stats to get the full picture.
Today Tango Therapeutics, Inc. has the market capitalization of ‪829.20 M‬, it has decreased by 0.54% over the last week.
No, TNGX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TNGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tango Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
TNGX reached its all-time high on Sep 17, 2021 with the price of 18.84 USD, and its all-time low was 2.47 USD and was reached on May 31, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 140.00 employees. See our rating of the largest employees — is Tango Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tango Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tango Therapeutics, Inc. stock shows the sell signal. See more of Tango Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Tango Therapeutics, Inc. future price: according to them, TNGX price has a max estimate of 20.00 USD and a min estimate of 16.00 USD. Read a more detailed Tango Therapeutics, Inc. forecast: see what analysts think of Tango Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Tango Therapeutics, Inc. EBITDA is ‪−109.98 M‬ USD, and current EBITDA margin is −305.96%. See more stats in Tango Therapeutics, Inc. financial statements.